(2024, March 11). Journey Medical Corporation Announces Presentation Of Data From Phase 1 Clinical Trial Assessing The Impact Of DFD-29 On Microbial Flora Of Healthy Adults At 2024 AAD Annual Meeting; Clinical Trial Achieved All Three Primary Objectives And Subjects Completed 16-Week Treatment With No Significant Safety Issues. Benzinga Newswires.
Chicago Style (17th ed.) Citation"Journey Medical Corporation Announces Presentation Of Data From Phase 1 Clinical Trial Assessing The Impact Of DFD-29 On Microbial Flora Of Healthy Adults At 2024 AAD Annual Meeting; Clinical Trial Achieved All Three Primary Objectives And Subjects Completed 16-Week Treatment With No Significant Safety Issues." Benzinga Newswires 11 Mar. 2024.
MLA (9th ed.) Citation"Journey Medical Corporation Announces Presentation Of Data From Phase 1 Clinical Trial Assessing The Impact Of DFD-29 On Microbial Flora Of Healthy Adults At 2024 AAD Annual Meeting; Clinical Trial Achieved All Three Primary Objectives And Subjects Completed 16-Week Treatment With No Significant Safety Issues." Benzinga Newswires, 11 Mar. 2024.